青霉素G钠(Penicillin G Sodium) - 药物靶点：PBPs_在研适应症：细菌性心内膜炎，脓毒症，链球菌感染_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Benzylpenicillin sodium、Penicillin G sodium (USP)、Crystapen

靶点

PBPs

作用机制

PBPs抑制剂(细菌青霉素结合蛋白家族抑制剂)

治疗领域

感染心血管疾病泌尿生殖系统疾病+ [1]

在研适应症

细菌性心内膜炎脓毒症链球菌感染+ [3]

非在研适应症-

原研机构

Pfizer Inc.

在研机构

Pfizer Inc.Seqirus Pty Ltd.

非在研机构-

最高研发阶段批准上市

首次获批日期

(1942-01-01),

细菌感染

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C16H18N2NaO4S

InChIKeyXFGIVHXZEANRAL-LQDWTQKMSA-N

CAS号69-57-8

关联

22

项与青霉素G钠相关的临床试验

NCT06726395

/ Recruiting临床4期

Randomized Controlled Clinical Trial Comparing Treatment with Cloxacillin Versus Benzylpenicillin in Bacteraemia Caused by Penicillin-susceptible Staphylococcus Aureus (PSSA)

The goal of this study is to investigate if benzylpenicillin is a better treatment option than cloxacillin in patients with penicillin-susceptible Staphylococcus aureus bacteraemia.

开始日期2024-12-01

申办/合作机构

Region Skåne Holding AB

NCT06262945

/ CompletedN/AIIT

Comparative Examination of the Postoperative Effects of Low-laser Treatment and Platelet-rich Fibrin Applications After Mandibular Impacted Wisdom Teeth Extraction

The aim of this study was investigate the comparison of postoperative effects of low laser treatment and platelet-rich fibrin application on mandibular impacted third molar tooth extraction. The study included a total of 60 patients with impacted mandibular third molar. Patients were evaluated in 4 randomly separated groups. In group 1, PRF was applied to the tooth socket. In group 2, PRF was applied to the tooth socket combined with Low Laser Treatment extraorally to the extraction area for three days within surgery day In group 3, Low Laser Treatment was applied to the extraorally to the extraction area for three days within surgery day. In group 4 (control group), tradional osteomy was made. The outcome variables were pain, swelling, the number of analgesics taken, and trismus. These variables were also assessed based on first, second, third, and seventh days following the operation. All of the 4 groups patients were prescribed an 875/125 mg amoxicillin/clavulanic acid tablet twice daily for five days.

开始日期2024-01-02

申办/合作机构

Near East University

NCT05137119

/ Recruiting临床4期IIT

Staphylococcus Aureus Network Adaptive Platform Trial

The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is an International Multi-Centered Randomised Adaptive Platform Clinical Trial to evaluate a range of interventions to reduce mortality for patients with Staphylococcus Aureus bacteraemia (SAB).

开始日期2022-02-16

申办/合作机构

University of Melbourne

[+13]

100 项与青霉素G钠相关的临床结果

登录后查看更多信息

100 项与青霉素G钠相关的转化医学

登录后查看更多信息

100 项与青霉素G钠相关的专利（医药）

登录后查看更多信息

208

项与青霉素G钠相关的文献（医药）

2025-02-01·FOOD CHEMISTRY

Solid phase extraction-surface enhanced Raman spectroscopy (SPE-SERS) test of antibiotic residues in Milk based on au@ MIL-101 NPs

Article

作者: He, Ting ; Hu, Jiming ; Gao, Mengyue ; Wang, LiHua ; Li, ZhiHao ; Jin, Fengmei ; Zhan, YiFang ; Yao, Qi ; Chen, Qiao

A SPE-SERS method was developed for the detection of several antibiotic residues in dairy products. Gold nanoparticles (Au NPs) encapsulated with an ultrathin Cr-MIL-101 shell (Au@Cr-MIL-101 NPs) have been synthesized, and the thickness of Cr-MIL-101 shell can be precisely controlled to 3 nm. As a superior solid phase extraction (SPE) adsorbent, Cr-MIL-101 acts as a shell layer to effectively enrich antibiotics within the localized surface plasmon resonance (LSPR) field of Au NPs, which enhances the SERS signal and eliminates background interference. The method can achieve highly sensitive and high-throughput detection for tetracycline hydrochloride, sulfapyridine and benzylpenicillin sodium in dairy products, and the detection limits (LOD) are as low as 2.237, 2.644 and 4.662 ppb respectively. The recoveries of antibiotic residues in spiked dairy products ranged from 72.31 % to 146.7 % with matrix effects (ME) of -15.13 % to 28.68 %. Thus, this method holds significant promise for rapid detection of antibiotics in milk.

2024-12-01·PHYTOCHEMISTRY

Stereuins A–F: Isopentenyl benzene congeners with antibacterial and neurotrophic activities from Stereum hirsutum HFG27

Article

作者: Liu, Ji-Kai

Cultivation and extraction of the fungus Stereum hirsutum (Willd.) Pers. yielded 12 isopentenyl benzene derivatives, including six previously undescribed derivatives, named stereuins A-F. Their structures were established based on NMR and mass spectroscopy analyses, supplemented by comparison with previously reported data. Stereuins A-C are unique benzoate derivatives containing fatty acid subunits. Stereuins D and E feature a valylene group and a 6/6/6 ring system. In vitro, stereuin A significantly promoted neurite outgrowth. Several compounds exhibited antibacterial activity against Staphylococcus aureus. Stereuin F has an IC₅₀ value of 5.2 μg/mL against S. aureus, comparable to the positive control, penicillin G sodium (1.4 μg/mL).

2024-11-20·BIOMEDICAL AND ENVIRONMENTAL SCIENCES

Diagnostic Value of Cerebrospinal Fluid Sequencing for Neurosyphilis with Cognitive Impairment.

Letter

作者: Yang, Ji ; Jin, Ning ; Chen, Bo ; Ji, Lingyun ; Chen, Xinxin

Neurosyphilis (NS) is an infectious disease caused by Treponema pallidum invading the central nervous system. It can manifest at any stage of syphilis, and is often misdiagnosed due to its atypical and progressive symptoms. The increasing incidence of NS underscores the necessity for early and accurate diagnosis. Here, we present a case where routine cerebrospinal fluid metagenomic next-generation sequencing (mNGS) was used to diagnose a patient with neurosyphilis. The patient exhibited cognitive impairment and was initially diagnosed with cerebral infarction due to syphilitic cerebral arteritis. Thus, the patient was treated with dual antiplatelet therapy (aspirin and clopidogrel) and statins to stabilize the plaques. Neurosyphilis was treated with penicillin sodium injections, resulting in significant improvement in the patient's mental state. This case is a rare instance of neurosyphilis associated with cerebral infarction. These findings suggest that mNGS is a valuable tool in diagnosing neurosyphilis, potentially improving diagnostic accuracy and patient outcomes.

50

项与青霉素G钠相关的新闻（医药）

2024-12-16

·米内网

【首仿】暴涨181%独家注射剂，科伦首家出击

精彩内容近日，CDE官网显示，科伦药业的苹果酸奈诺沙星氯化钠注射液以仿制4类报产并获受理。这是一款新型的无氟喹诺酮类抗菌药，2023年在中国公立医疗机构终端的销售额增速约为181%，目前仅浙江医药新昌制药拥有生产批文。苹果酸奈诺沙星氯化钠注射液属于国产1类新药，是一款新型的无氟喹诺酮类抗菌药，具有广谱的抗革兰阴性菌、革兰阳性菌和非典型病原菌的生物活性，可用于治疗已证明或高度怀疑由敏感细菌引起的感染，如社区获得性肺炎等。米内网数据显示，苹果酸奈诺沙星氯化钠注射液已通过谈判纳入国家医保乙类目录，近年来在中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端迅速放量，2023年销售额超过1亿元，同比增长约181%。目前国内仅浙江医药新昌制药拥有苹果酸奈诺沙星氯化钠注射液生产批文，尚无仿制药获批上市，科伦药业的产品于近日以仿制4类提交上市申请并获受理，为国产首家。在全身用抗感染领域，科伦药业拥有140多个产品的生产批文，其中有50个已过评或视同过评，包括41个全身用抗细菌药、5个全身用抗真菌药及4个全身用抗病毒药。多个品种为国内首家过评，其中泊沙康唑口服混悬液、注射用美罗培南/氯化钠注射液、注射用头孢他啶阿维巴坦钠/氯化钠注射液、注射用头孢西丁钠/葡萄糖注射液、阿奇霉素分散片、注射用头孢他啶/5%葡萄糖注射液等品种独家过评。科伦药业已过评的全身用抗感染药物来源：米内网一致性评价进度数据库此外，注射用青霉素钠、左氧氟沙星注射液、注射用亚胺培南西司他丁钠/氯化钠注射液、注射用头孢唑林钠/氯化钠注射液、注射用头孢他啶/氯化钠注射液、注射用比阿培南/氯化钠注射液、吗啉硝唑氯化钠注射液、注射用头孢唑肟钠/氯化钠注射液、苹果酸奈诺沙星氯化钠注射液等品种以新注册分类报产在审，其中注射用亚胺培南西司他丁钠/氯化钠注射液、注射用比阿培南/氯化钠注射液、注射用头孢唑肟钠/氯化钠注射液等品种暂无企业获批。资料来源：米内网数据库、CDE官网等注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至12月16日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com 稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

一致性评价上市批准

2024-11-27

·echemi

Lyfius Pharma Invests 25 Billion Rupees to Build the World's Largest Penicillin G Factory

Lyfius Pharma Pvt Ltd, a manufacturer of penicillin G, announced the launch of its state-of-the-art manufacturing facility in Kakinada, Andhra Pradesh, on October 29th. The company has invested 25 billion rupees in the plant, which has an annual production capacity of 15,000 tons, under the Production Linked Incentive (PLI) scheme. The facility was inaugurated online by Prime Minister Narendra Modi, with the presence of several Indian ministers, including Chemicals and Fertilizers Minister Jagat Prakash Nadda, Labour and Employment Minister Mansukh Mandaviya, and others. Lyfius Pharma's director, MV Rama Krishna, highlighted the significance of the Pen-G factory's launch as a milestone in strengthening local production and reducing reliance on imported key drug components. The investment underscores the company's commitment to the government's vision of "Atmanirbhar Bharat" (Self-Reliant India), aiming to establish India as a global pharmaceutical manufacturing hub. The company expects commercial production to accelerate in the fiscal year 2025, enhancing domestic output of key starting materials (KSM), drug intermediates (DI), and active pharmaceutical ingredients (API). Lyfius Pharma, a subsidiary of Aurobindo Pharma, operates the advanced facility in Andhra Pradesh, which is one of India's largest fermentation-based antibiotic intermediate plants, featuring large-capacity fermenters and automated starch and glucose plants. The project feasibility report outlines the production of 2,000 tons/year of 7-ACA, 15,000 tons/year of penicillin G, 198,000 tons/year of glucose, and 4,200 tons/year of 6-APA, with co-line products including 1,800 tons/year of amoxicillin trihydrate (enzyme method) and 1,800 tons/year of ampicillin trihydrate (enzyme method). Aurobindo Pharma's Q2FY2025 financial results show an 8.0% year-over-year increase in revenue to 77.96 billion rupees, with an EBITDA of 19.54 billion rupees before research and development, a profit margin of 25.1%, and a net profit of 8.17 billion rupees, up 8.6%. The company's performance indicates positive growth trends, particularly in Europe and growth markets, despite a 22.8% decline in ARV (antiretroviral) business revenue. The API business maintained stable revenue at 11.56 billion rupees, contributing 14.8% to total revenue.

财报

2024-11-20

·赛柏蓝

第十批国采40个注射剂迎战，涉倍特、石四药、科伦、齐鲁...

编者按：本文来米内网，作者未晞；赛柏蓝授权转载，编辑凯西 11月初，第十批国采药品信息填报工作启动，据业内消息集采文件即将发布；本次目录涉及注射剂40个，2023年在中国公立医疗机构终端的合计销售规模超过300亿元。 01 40个注射剂将展开激战图1：40个注射剂涉及的大类情况从大类来看，心脑血管系统药物占比最大，有11个，全身用抗感染药物占了9个，血液和造血系统药物占了6个，杂类、消化系统及代谢药、抗肿瘤和免疫调节剂各有3个，神经系统药物、呼吸系统用药各有2个，生殖泌尿系统和性激素类药物有1个。关注赛柏蓝，进入主页发消息界面发送【第十批】获取第十批药品填报范围PDF~ 表1：销售额TOP10注射剂注：竞争企业统计截至11月19日 8个超10亿注射剂入围第十批国采：盐酸多柔比星脂质体注射液2023年在中国公立医疗机构终端的销售额达38.7亿元，目前竞争企业（原研+过评）有8家；盐酸艾司洛尔注射液2023年在中国公立医疗机构终端的销售额达10.8亿元，目前竞争企业（原研+过评）有18家。表2：竞争企业TOP11注射剂注：销售额低于1亿元用*表示，竞争企业统计截至11月19日目前竞争企业最多的是间苯三酚注射液，达33家；帕拉米韦注射液、己酮可可碱注射液、盐酸多巴酚丁胺注射液、舒更葡糖钠注射液4个产品的竞争企业超过20家。注射用尼可地尔、盐酸艾司洛尔注射液、注射用盐酸罗沙替丁醋酸酯、注射用哌拉西林钠、氯化钾注射液、拉考沙胺注射液、泊沙康唑注射液、氟尿嘧啶注射液、注射用氨苄西林钠舒巴坦钠、碳酸氢钠林格注射液、氨茶碱注射液、注射用青霉素钠、重酒石酸间羟胺注射液、硝酸异山梨酯注射液、左西孟旦注射液、注射用氨苄西林钠、重酒石酸去甲肾上腺素注射液、乳酸环丙沙星氯化钠注射液、硫酸阿米卡星注射液、盐酸纳洛酮注射液、尼莫地平注射液、卡前列素氨丁三醇注射液、氨基己酸注射液23个产品的竞争企业在10家（含）以上。 02 倍特、石家庄四药、科伦、齐鲁...蓄势待发图2：入围注射剂≥10个的企业集团倍特药业有16个注射剂迎战第十批国采，涉及全身用抗感染药物（7个）、心脑血管系统药物（4个）、消化系统及代谢药（2个）、血液和造血系统药物（2个）、杂类（1个）。超10亿产品包括了重酒石酸去甲肾上腺素注射液、注射用哌拉西林钠、重酒石酸间羟胺注射液、注射用氨苄西林钠。石家庄四药有15个注射剂迎战第十批国采，涉及心脑血管系统药物（6个）、血液和造血系统药物（4个）、呼吸系统用药（2个）、全身用抗感染药物（1个）、神经系统药物（1个）、消化系统及代谢药（1个）。超10亿产品包括了重酒石酸去甲肾上腺素注射液、盐酸艾司洛尔注射液。科伦药业有12个注射剂迎战第十批国采，涉及全身用抗感染药物（5个）、血液和造血系统药物（4个）、消化系统及代谢药（1个）、心脑血管系统药物（1个）、杂类（1个）。超10亿产品包括了注射用哌拉西林钠、注射用氨苄西林钠。齐鲁制药有11个注射剂迎战第十批国采，涉及全身用抗感染药物（4个）、心脑血管系统药物（3个）、抗肿瘤和免疫调节剂（2个）、消化系统及代谢药（1个）、杂类（1个）。超10亿产品包括了盐酸多柔比星脂质体注射液、注射用哌拉西林钠、盐酸艾司洛尔注射液。扬子江药业有10个注射剂迎战第十批国采，涉及心脑血管系统药物（3个）、全身用抗感染药物（2个）、消化系统及代谢药（2个）、神经系统药物（1个）、生殖泌尿系统和性激素类药物（1个）、杂类（1个）。超10亿产品有注射用盐酸罗沙替丁醋酸酯。此外，石药控股、杭州沐源生物各有9个注射剂迎战第十批国采，重庆药友制药、远大医药各有8个注射剂迎战第十批国采，华润双鹤、福安药业各有7个注射剂迎战第十批国采……240多个企业集团将参与激战，谁将成为大赢家，我们静待开标结果。附：第十批集采药品填报范围 END 内容沟通：郑瑶（13810174402）左下角「关注账号」，右下角「在看」，防止失联

带量采购

100 项与青霉素G钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05408	-	S01AA14 J01CE01	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
细菌性心内膜炎	澳大利亚	Seqirus Pty Ltd.	1991-11-04
脓毒症	澳大利亚	Seqirus Pty Ltd.	1991-11-04
链球菌感染	澳大利亚	Seqirus Pty Ltd.	1991-11-04
手术伤口感染	澳大利亚	Seqirus Pty Ltd.	1991-11-04
梅毒	澳大利亚	Seqirus Pty Ltd.	1991-11-04
细菌感染	-	Pfizer Inc.	1942-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


AAAAI2023	N/A	青霉素过敏	-	Penicillin Skin Testing	鹽製鏇醖淵糧艱衊餘獵(齋壓蓋憲衊獵壓繭願獵) = 網餘艱壓膚願艱築繭顧繭簾齋壓構築觸簾齋製 (壓觸鏇築範鑰鏇簾簾鑰 ) 更多	-	2023-02-01
				Penicillin (2-Step Direct Challenge)	網鬱醖糧簾糧顧積觸鑰(鑰糧繭築網繭網築夢鏇) = 鏇鏇選鬱網選繭獵遞顧鑰簾廠願顧網夢願膚獵 (築鹹淵築築夢遞鏇繭衊 ) 更多
AAAAI2023	N/A	-	-	Amoxicillin challenge	網窪醖選製顧窪衊膚夢(觸壓齋願構齋獵鑰構遞) = 選獵遞餘顧膚遞壓繭遞積鹹繭襯鹹艱簾繭蓋蓋 (範積網夢遞積構願襯築 )	-	2023-02-01
NCT01255670 (CTgov)	N/A	扁桃体周脓肿	200	metronidazole+penicillin (Penicillin and Metronidazole)	窪鬱鑰鬱鏇糧鬱鹹願觸(鬱鹽艱鏇餘蓋範願衊廠) = 鬱憲糧構膚窪積憲願鹽構鬱餘繭淵網壓選選鑰 (壓淵築艱膚淵鏇獵餘顧, 憲觸範壓淵構餘襯壓憲 ~ 憲襯壓製襯醖遞餘鹹鹹) 更多	-	2021-05-11
				metronidazole+penicillin (Penicillin and Placebo)	窪鬱鑰鬱鏇糧鬱鹹願觸(鬱鹽艱鏇餘蓋範願衊廠) = 醖鬱淵糧獵鑰願範願壓構鬱餘繭淵網壓選選鑰 (壓淵築艱膚淵鏇獵餘顧, 鏇獵鑰簾繭遞鬱餘簾範 ~ 齋觸廠淵壓壓壓夢壓糧) 更多
AAAAI2021	N/A	-	452	penicillin (PST alone)	觸糧繭衊憲膚鹹獵鏇積(選鹹憲遞淵觸壓淵憲壓) = 築網願選獵築獵憲遞顧憲憲鏇鏇選鹽積齋願衊 (淵積憲襯簾鑰願觸醖衊 )	积极	2021-02-01
				penicillin (PST and oral drug challenge)	觸糧繭衊憲膚鹹獵鏇積(選鹹憲遞淵觸壓淵憲壓) = 廠糧構鏇築窪壓繭憲製憲憲鏇鏇選鹽積齋願衊 (淵積憲襯簾鑰願觸醖衊 )
EHA2019	N/A	镰状细胞血症	133	PENICILLIN PROPHYLAXIS (Patients on antibiotic prophylaxis)	憲構醖網艱鬱醖顧鬱構(觸膚鬱鏇艱遞網積築鹽) = 觸蓋壓淵製襯憲衊網艱鹽齋構獵遞繭窪範鹹窪 (選鹹窪窪餘夢遞製構網 )	-	2019-06-14
				PENICILLIN PROPHYLAXIS (Patients not on antibiotic prophylaxis)	壓窪壓醖膚願鑰簾遞遞(艱餘鑰構鹽齋繭範鑰鹹) = 夢齋糧繭憲選廠壓鹽糧範願鬱鑰鑰鏇遞構衊蓋 (憲繭廠淵糧鏇獵構構廠 )
AAAAI2019	N/A	-	-	Oral clindamycin	構獵觸範鹽憲窪繭憲選(積醖繭膚糧膚觸鏇窪製) = 鏇齋顧衊襯鹹獵蓋壓鑰願製餘淵鑰淵遞襯構齋 (壓網遞積繭願艱網構襯, 1in685 ~ 460)	-	2019-02-01
				Parenteral clindamycin	構獵觸範鹽憲窪繭憲選(積醖繭膚糧膚觸鏇窪製) = 築窪衊醖鹽餘糧築醖觸願製餘淵鑰淵遞襯構齋 (壓網遞積繭願艱網構襯, 1in685 ~ 460)
ASN2013	N/A	梅毒 \| 肾小球肾炎 HIV \| RPR \| Treponema pallidum particle agglutination assay	1	Penicillin	襯鏇齋齋鹽衊憲繭鑰構(築網窪鬱憲衊獵衊艱網) = 構顧艱構壓繭鹹齋夢齋鬱遞積鑰遞獵構糧糧網 (襯簾鬱憲網襯構衊積簾 )	积极	2013-11-05
AAAAI2005	N/A	链球菌感染 \| 青霉素过敏 penicillin allergy	47	Penicillin (PST negative)	構獵襯鹹顧憲簾廠選鬱(簾鏇鏇鹹鑰淵鬱壓鏇鬱) = There were 2 delayed onset rashes associated with peripartum penicillins 鬱範鏇糧獵築蓋蓋醖願 (鏇觸鬱襯鏇淵積齋繭範 ) 更多	-	2005-03-21
IAS2004	N/A	神经梅毒	31	intravenous Penicillin G (HIV-positive patients with serological examined SI)	憲願衊獵衊衊衊衊鑰糧(願餘糧艱襯鹽願鬱齋繭) = 鑰憲醖遞鏇糧繭膚願憲顧餘蓋築鬱築獵遞艱觸 (製衊製夢鏇窪顧構夢憲 ) 更多	-	2004-01-01
Pubmed \| J Antimicrob Chemother	N/A	-	-	Benzylpenicillin	簾獵簾範鑰鏇網鹹簾選(蓋獵餘襯廠築願餘鬱糧) = 餘鏇鏇襯鏇糧餘廠鹹願觸鏇積鹽淵壓夢膚齋顧 (願淵顧壓艱遞艱築鏇簾 )	-	1988-01-01
				Imipenem/cilastatin	簾獵簾範鑰鏇網鹹簾選(蓋獵餘襯廠築願餘鬱糧) = 簾築糧憲壓積鏇憲廠鹹觸鏇積鹽淵壓夢膚齋顧 (願淵顧壓艱遞艱築鏇簾 )